emperor-preserved-heart-failure-toplineresults
Breakthrough results for empagliflozin confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction  The EMPEROR-Preserved Phase III trial met its primary endpoint and demonstrated significant risk reduction with empagliflozin for the composite of cardiovascular death or hospitalization for heart failure in patients with heart failure with preserved ejection fraction (HFpEF)HFpEF has been classified as “the single largest unmet need in cardiovascular medicine”1 based on prevalence, poor outcomes and the absence of clinically proven therapies to date2W...
Source: Boehringer Ingelheim Corporate News - July 6, 2021 Category: Research Source Type: news

Synjardy XR (empagliflozin and metformin extended-release)
Title: Synjardy XR (empagliflozin and metformin extended-release)Category: MedicationsCreated: 7/2/2021 12:00:00 AMLast Editorial Review: 7/2/2021 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - July 2, 2021 Category: Endocrinology Source Type: news

Synjardy (empagliflozin and metformin)
Title: Synjardy (empagliflozin and metformin)Category: MedicationsCreated: 6/30/2021 12:00:00 AMLast Editorial Review: 6/30/2021 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - June 30, 2021 Category: Drugs & Pharmacology Source Type: news

Glyxambi (empagliflozin and linagliptin)
Title: Glyxambi (empagliflozin and linagliptin)Category: MedicationsCreated: 6/29/2021 12:00:00 AMLast Editorial Review: 6/29/2021 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - June 29, 2021 Category: Endocrinology Source Type: news

real-world-benefit-shown-in-T2D-treatment
Empagliflozin reduced the risk of cardiovascular events and hospitalization for heart failure compared to DPP-4 inhibitors in people with type 2 diabetes  Interim analysis of the EMPRISE real-world evidence study showed that empagliflozin was associated with a reduced risk in all-cause mortality, hospitalization for heart failure and acute kidney injury requiring dialysis, compared to DPP-4 inhibitorsThis analysis, which includes European data pooled with data from Israel and East Asia, was presented for the first time at the American Diabetes Association Scientific Sessions, 25 June 20211  EMPRISE data complemen...
Source: Boehringer Ingelheim Corporate News - June 28, 2021 Category: Research Source Type: news

reduced-heart-failure-treatment-approval-europe
Jardiance ® (empagliflozin) approved in Europe for the treatment of heart failure with reduced ejection fractionThis new indication is based on the EMPEROR-Reduced trial, which showed a significant 25 percent reduction in the combined relative risk versus placebo of cardiovascular death or hospitalization for heart failure with reduced ejection fraction in adults with or without diabetes and an eGFR of ≥20ml/min/1.73 m2Heart failure is the leading cause of hospitalization in Europe,   with prevalence expected to increase as the population agesJardiance was first approved in May 2014 for the treatment of adults ...
Source: Boehringer Ingelheim Corporate News - June 21, 2021 Category: Research Source Type: news

Pill for diabetics could also protect against heart failure
The medication, empagliflozin, is thought to stimulate the heart, making it more efficient and leading to 'significant improvements' in function after just three months. (Source: the Mail online | Health)
Source: the Mail online | Health - June 12, 2021 Category: Consumer Health News Source Type: news

emperor-reduced-chmp-positive-opinion
CHMP issues positive opinion for Jardiance ® (empagliflozin) for the treatment of adults with heart failure with reduced ejection fractionThe positive opinion is based on the EMPEROR-Reduced trial, which showed a significant 25 percent reduction in the combined relative risk of cardiovascular death or hospitalization for heart failure  The results were observed in adults with heart failure with reduced ejection fraction (HFrEF), with or without diabetesJardiance is currently indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 21, 2021 Category: Research Source Type: news

Empagliflozin cost effective in patients with T2DM and CVD
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - May 1, 2021 Category: Drugs & Pharmacology Source Type: news

Empagliflozin least costly option for preventing heart failure in T2DM patients?
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - May 1, 2021 Category: Drugs & Pharmacology Source Type: news

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Cardiac and Kidney Benefits of Empagliflozin in Heart Failure
This study examined the effect of empagliflozin on cardiovascular and kidney outcomes in heart failure patients with or without chronic kidney disease.Circulation (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - March 30, 2021 Category: Transplant Surgery Tags: Cardiology Journal Article Source Type: news

PHARMAC approves funding for empagliflozin and dulaglutide
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - January 1, 2021 Category: Drugs & Pharmacology Source Type: news

Jardiance ® associated with a total cost of care savings of more...
Highmark and Boehringer Ingelheim announced positive results from their outcomes-based agreement, which showed that adults with type 2 diabetes and known cardiovascular disease who took...(PRWeb December 15, 2020)Read the full story at https://www.prweb.com/releases/jardiance_associated_with_a_total_cost_of_care_savings_of_more_than_20_according_to_results_from_an_outcomes_based_agreement_between_boehringer_ingelheim_and_highmark/prweb17613452.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 15, 2020 Category: Pharmaceuticals Source Type: news

empa-reg-outcome-recurrent-events
Empagliflozin reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME ® trialIn new results published in The Lancet Diabetes& Endocrinology, empagliflozin reduced the risk of total (first plus recurrent) cardiovascular events including 3P-MACE, hospitalization for heart failure and all-cause hospitalization versus placebo in adults with type 2 diabetes and established cardiovascular diseaseRecurrent cardiovascular events in people with type 2 diabetes are responsible for considerable clinical and s...
Source: Boehringer Ingelheim Corporate News - November 18, 2020 Category: Research Source Type: news

Empagliflozin Favorably Reshaped LVs in HFrEF Patients Empagliflozin Favorably Reshaped LVs in HFrEF Patients
Treatment with the SGLT2 inhibitor empagliflozin led to significant reductions in both left ventricular end systolic and diastolic volumes in two independent randomized studies of patients with heart failure with reduced ejection fraction.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 15, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

October 9 2020 This Week in Cardiology October 9 2020 This Week in Cardiology
COVID-19, scientific philosophy, left main coronary artery disease, empagliflozin and the SGLT2 inhibitors are the topics discussed by John Mandrola, MD in this week ’ s podcasttheheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 9, 2020 Category: Cardiology Tags: Cardiology Commentary Source Type: news

Empagliflozin's HFrEF Benefit Steady With Sacubitril/Valsartan Empagliflozin's HFrEF Benefit Steady With Sacubitril/Valsartan
The SGLT2 inhibitor empagliflozin works just as well when added on top of a second major agent used to treat patients with heart failure and reduced ejection fraction.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 7, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

Empagliflozin Superior to Placebo for Heart Failure
WEDNESDAY, Sept. 2, 2020 -- Among patients with heart failure, risk for cardiovascular death or hospitalization with heart failure is lower for those receiving empagliflozin compared with placebo, according to a study published online Aug. 29 in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 2, 2020 Category: Pharmaceuticals Source Type: news

SGLT2 Inhibitors in HFrEF: Putting EMPEROR-Reduced in Context SGLT2 Inhibitors in HFrEF: Putting EMPEROR-Reduced in Context
Dr Ileana Pi ñ a asks the lead investigator how his trial on empagliflozin in HFrEF compares with DAPA-HF. They speculate on the likely mechanism of action of these relatively new drugs.theheart.org on Medscape (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - September 1, 2020 Category: Intensive Care Tags: Cardiology Commentary Source Type: news

Empagliflozin's HFrEF Benefit Solidifies Class Effects Empagliflozin's HFrEF Benefit Solidifies Class Effects
The 25% cut in primary endpoints among patients with HFrEF receiving empagliflozin in EMPEROR-Reduced matched the benefit seen before from dapagliflozin in DAPA-HF.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 29, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

Positive Top-line Results for Another SGLT2 Inhibitor in HF Positive Top-line Results for Another SGLT2 Inhibitor in HF
Empagliflozin reduced the risk of CV death or heart failure hospitalization in a phase 3 trial of adults with HF and reduced ejection fraction.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - July 31, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

Jardiance(R) meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in phase III trial in adults with and without diabetes
Jardiance (empagliflozin) significantly reduced the risk of cardiovascular death or hospitalization for heart failure versus placebo in the EMPEROR-Reduced heart failure trial. The study evaluated adults with heart failure with reduced ejection fraction ... Biopharmaceuticals, Endocrinology Eli Lilly, Jardiance, empagliflozin, diabetes (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 30, 2020 Category: Pharmaceuticals Source Type: news

emperor-reduced-heart-failure-toplineresults
Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetesEmpagliflozin significantly reduced the risk of cardiovascular death or hospitalization for heart failure versus placebo in the EMPEROR-Reduced heart failure trial. The study evaluated adults with heart failure with reduced ejection fraction  Treatment of heart failure is an important unmet need with over half of those diagnosed dying within five years1 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 30, 2020 Category: Research Source Type: news

Empagliflozin 2nd-line therapy in T2DM: better outcomes, lower cost in US
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 30, 2020 Category: Drugs & Pharmacology Source Type: news

EMPA-REG OUTCOME: Empagliflozin Cuts Insulin Need in Type 2 Diabetes EMPA-REG OUTCOME: Empagliflozin Cuts Insulin Need in Type 2 Diabetes
The SGLT2 inhibitor reduced the need to start insulin treatment or intensify existing insulin treatment compared with placebo in a post-hoc analysis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 14, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

DCRI-collaboration-empact-mi
Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining empagliflozin ’s effects following an acute myocardial infarction Ischemic heart disease, including myocardial infarction, is the leading cause of death in the world1EMPACT-MI is the first trial in the SGLT2 inhibitor class to investigate the prevention of heart failure after acute myocardial infarction in adults with and without diabetesThe trial is part of the EMPOWER clinical trial program, the broadest and most comprehensive of any SGLT2 inhibitor, exploring the impact of empagliflozin on the li...
Source: Boehringer Ingelheim Corporate News - May 26, 2020 Category: Research Source Type: news

Fda-crl-t1d
US FDA issues complete response letter for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 20, 2020 Category: Research Source Type: news

FDA-Fast-Track-chronic-kidney-disease
U.S. FDA grants Fast Track designation to empagliflozin for the treatment of chronic kidney disease (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 12, 2020 Category: Research Source Type: news

Trijardy XR (Empagliflozin, Linagliptin, and Metformin Hydrochloride Extended-release Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 14, 2020 Category: Drugs & Pharmacology Source Type: news

Trijardy XR (Empagliflozin, Linagliptin, and Metformin Hydrochloride Extended-release Tablets) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 5, 2020 Category: Drugs & Pharmacology Source Type: news

Monthly News Roundup - January 2020
Trijardy XR: A Triple Drug Combo Approved for Type 2 Diabetes In January, the US Food and Drug Administration (FDA) approved once-daily Trijardy XR (empagliflozin, linagliptin, and metformin hydrochloride extended release tablets) to lower blood... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 31, 2020 Category: Pharmaceuticals Source Type: news

FDA OKs New Triple-Combo Pill, Trijardy XR, for Type 2 Diabetes FDA OKs New Triple-Combo Pill, Trijardy XR, for Type 2 Diabetes
The once-daily treatment comprises empagliflozin (Jardiance), linagliptin (Tradjenta), and extended-release metformin hydrochloride. It will be available in four different dosages.FDA Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 28, 2020 Category: Cardiology Tags: Diabetes & Endocrinology News Alert Source Type: news

FDA Approves Trijardy XR (empagliflozin/linagliptin/metformin) for Type 2 Diabetes in Adults
RIDGEFIELD, Conn., and INDIANAPOLIS, Jan. 27, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Trijardy XR (empagliflozin/linagliptin/metformin hydrochloride extended release tablets) to lower blood sugar in adults with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 27, 2020 Category: Drugs & Pharmacology Source Type: news

Lilly, Boehringer's Jardiance has heart failure trial setback
Boehringer Ingelheim and Eli Lilly announced failing results in two trials evaluating Jardiance in adults with chronic heart failure. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - December 13, 2019 Category: Pharmaceuticals Source Type: news

EMPERIAL-heart-failure-toplineresults
Boehringer Ingelheim and Lilly provide update on empagliflozin phase III exercise ability studies in chronic heart failure (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 13, 2019 Category: Research Source Type: news

EMPRISE-interim-analysis
Interim analysis from EMPRISE real-world study shows empagliflozin decreased risk of hospitalisation for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonistsThis analysis on effectiveness also shows empagliflozin was associated with a similar risk of non-fatal atherosclerotic cardiovascular events compared with DPP-4 inhibitors or GLP-1 receptor agonists1  A second analysis on healthcare resource utilisation shows empagliflozin was associated with a reduced risk in all-cause hospitalisations compared with DPP-4 inhibitors2 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 17, 2019 Category: Research Source Type: news

FDA Panel Rejects Empagliflozin for Use in Type 1 Diabetes FDA Panel Rejects Empagliflozin for Use in Type 1 Diabetes
The FDA advisers said the pivotal approval study was too short and did not involve enough patients to characterize efficacy or safety.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - November 14, 2019 Category: Drugs & Pharmacology Tags: Diabetes & Endocrinology News Source Type: news

Empulse
Boehringer Ingelheim and Lilly initiate first ever study to assess empagliflozin in people hospitalised for acute heart failure who have been stabilisedEMPULSE is a superiority study that will assess the clinical benefit, safety and tolerability of 10 mg daily empagliflozin in acute heart failure1  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 12, 2019 Category: Research Source Type: news

' Best in Class' Diabetes Drugs Compared in Head-to-Head Trial'Best in Class' Diabetes Drugs Compared in Head-to-Head Trial
A1c was reduced significantly more with oral semaglutide versus empagliflozin in a comparison of the type 2 diabetes drugs, but the former still lacks evidence of CV efficacy.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 11, 2019 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

New Focus for Boehringer Ingelheim and Lilly Alliance
Boehringer Ingelheim and Lilly modernise alliance to focus full expertise on Jardiance ®Alliance to focus combined expertise and investment to maximise Jardiance ®for people with type 2 diabetes, heart failure, and chronic kidney diseaseAlliance to continue to include three product families – empagliflozin, linagliptin  and insulin glargine (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 4, 2019 Category: Research Source Type: news

cardiovascular-risk-factors
Consistent cardiovascular benefits shown with empagliflozin treatment regardless of the number of controlled cardiovascular risk factorsPost-hoc analysis of the EMPA-REG OUTCOME ® trial in adults with type 2 diabetes and established cardiovascular disease examined the cardiovascular benefits of empagliflozin based on the number of cardiovascular risk factor goals achieved.1Findings from the post-hoc analysis were presented at the 55th Annual Meeting of the European Association for the Study of Diabetes.1  This analysis suggests that, independent of the number of risk factor goals achieved, empagliflozin demonstrat...
Source: Boehringer Ingelheim Corporate News - September 19, 2019 Category: Research Source Type: news

Empagliflozin in T2DM: long-term benefits at acceptable costs
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 30, 2019 Category: Drugs & Pharmacology Source Type: news

U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure
Fast Track designation facilitates development of new therapies that treat serious conditions and fulfill an unmet medical need FDA's Fast Track designation for empagliflozin underscores the urgent need for new potential treatment options for the 6.5 mi... Biopharmaceuticals, Cardiology, FDA Eli Lilly, Boehringer Ingelheim, empagliflozin, JARDIANCE, heart failure (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 26, 2019 Category: Pharmaceuticals Source Type: news

FDA-fast-track-designation-chronic-heart-failure
US FDA grants Fast Track designation to empagliflozin for the treatment of chronic heart failureFast Track designation facilitates the development of new therapies that treat serious conditions and fulfill an unmet medical need.  FDA ’s Fast Track designation for empagliflozin underscores the urgent need for new potential treatment options for the 26 million people affected by chronic heart failure worldwide, including 6.5 million in the US.1,2 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 26, 2019 Category: Research Source Type: news

Effects of Empagliflozin on Metabolic Parameters in PCOS Effects of Empagliflozin on Metabolic Parameters in PCOS
In what ways might treatment with empagliflozin impact the metabolic parameters in women with PCOS?Clinical Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 12, 2019 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

type-2-diabetes-cardiorenal-post-hoc-analysis
New post-hoc analysis shows consistent cardiorenal risk reductions of empagliflozin in a sub-group of adults with type 2 diabetes and chronic kidney disease without overt proteinuriaFindings from a post-hoc analysis of the EMPA-REG OUTCOME ® trial in adults with type 2 diabetes and chronic kidney disease without overt proteinuria were presented at the 79th American Diabetes Association Scientific Sessions® (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 10, 2019 Category: Research Source Type: news

effectiveness-analysis-in-diabetic-kidney-disease-and-type-2-diabetes
New post-hoc analysis of EMPA-REG OUTCOME ® examined cost-effectiveness of empagliflozin versus standard of care in a subgroup of people with type 2 diabetes and diabetic kidney disease Empagliflozin, in addition to standard of care, has the potential to improve economic outcomes for people with type 2 diabetes and established cardiovascular disease who also have diabetic kidney disease, from a US payer perspective1  Cost effective analysis used modeling and simulations based on subgroup data from EMPA-REG OUTCOME ® to predict clinical events and estimated costs for people with type 2 diabetes and diabeti...
Source: Boehringer Ingelheim Corporate News - April 14, 2019 Category: Research Source Type: news

EMPRISE real-world study results
Initial results from the EMPRISE real-world study of empagliflozin compared with DPP-4 inhibitors presented at ACC.19 and AMCP 2019  EMPRISE is an ongoing real-world evidence study in 35,000 people with type 2 diabetes in the US, comparing empagliflozin with DPP-4 inhibitors; initial results based on the first two years of the study were presented at AMCP 2019 and ACC.191,2Initial results presented at AMCP 2019 showed empagliflozin was associated with reductions in all-cause hospitalisations compared with DPP-4 inhibitors, and significantly fewer recurrent emergency department visits and physician office visits1Initia...
Source: Boehringer Ingelheim Corporate News - March 28, 2019 Category: Research Source Type: news

Empa ACC Expert Consensus Decision Pathway
American College of Cardiology recommends empagliflozin as preferred SGLT2 inhibitor for adults with type 2 diabetes and established cardiovascular disease in new Expert Consensus Decision Pathway (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 23, 2018 Category: Research Source Type: news

Empagliflozin May Reduce LV Mass in Patients With CVD, Diabetes Empagliflozin May Reduce LV Mass in Patients With CVD, Diabetes
EMPA-HEART Cardiolink-6 trial results suggest that the SGLT2 inhibitor is linked to reduced left ventricular mass, a surrogate for reduced heart failure, in patients with CVD and type 2 diabetes.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 13, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news